Asthma management with triple ICS/LABA/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement.

Rossella LaitanoLuigino CalzettaMatteo MatinoElena PistocchiniRogliani Paola

Published in: Expert opinion on pharmacotherapy (2024)

The findings of this umbrella review suggest an optimization of ICS dose in triple ICS/LABA/LAMA combination, based on the severity of exacerbation and type 2 biomarkers expression.

Keyphrases

chronic obstructive pulmonary disease
muscular dystrophy
poor prognosis
lung function
meta analyses
randomized controlled trial
intensive care unit
allergic rhinitis
acute respiratory distress syndrome